BioSpace News Archive

Lyra Therapeutics , Inc. today announced that Maria Palasis, Ph.D., President and Chief Executive Officer, will participate in the following investor conferences in September.

Apnimed announced that a post-hoc analysis of data from the MARIPOSA Phase 2b trial, an efficacy, safety and dose-finding study for AD109 (aroxybutynin/atomoxetine) of one-month duration, will be featured at a poster presentation at the European Respiratory Society’s (ERS) International Congress 2023 in Milan, Italy.

MaxCyte, Inc. today announced the appointment of Ali Soleymannezhad as Executive Vice President of Bioprocessing, effective August 21, 2023.

Elicio Therapeutics, Inc. today announced that Robert Connelly, Chief Executive Officer, will present at the upcoming H.C. Wainwright 25th Annual Global Investment Conference on September 13, 2023 at 9:30 a.m. ET.

Onconova Therapeutics, Inc. today announced that Steven Fruchtman, M.D., President & CEO, will participate in the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023.

VYNE Therapeutics Inc. today announced that David Domzalski, President and Chief Executive Officer, will participate in the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023.

ALX Oncology Holdings Inc. today announced that Jason Lettmann, a member of the Board of Directors, will succeed Jaume Pons, Ph.D. as Chief Executive Officer, effective September 6, 2023.

X4 Pharmaceuticals today announced that management will be participating in a fireside chat at the upcoming Morgan Stanley 21st Annual Global Healthcare Conference in New York City.

Ocular Therapeutix, Inc. today announced that it will participate at the following conferences: H.C. Wainwright 25th Annual Global Investment Conference Date: Tuesday, September 12, 2023.

Journey Medical Corporation announced it has entered into an exclusive license agreement with Maruho Co., Ltd., a Japanese company specializing in dermatology and also Journey’s exclusive licensing partner that developed and is commercializing Qbrexza in Japan.